BioNano Genomics Inc vs Global X Cloud Computing ETF — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Global X Cloud Computing ETF trades at $27.74. The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CLOU | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.92 | $28.09 |
52-Week Low | $1.06 | $17.60 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
CLOU, the Global X Cloud Computing ETF, trades at $27.66, down 1.53% on the day, with a bullish technical signal from moving averages and ADX indicators. The ETF provides diversified exposure to cloud computing stocks, with recent news highlighting long-term growth potential beyond AI hype, driven by strong holdings like Snowflake and Datadog. RSI levels above 80 indicate overbought conditions, suggesting near-term caution.
The outlook for CLOU remains positive due to structural growth in cloud adoption, though high RSI readings and competition from other cloud ETFs pose risks. Investor sentiment is buoyed by resilient subscription revenues and diversification benefits, but volatility in tech stocks and macroeconomic pressures could impact performance.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →